Additional Study Information: This is an open label, Phase 1b/2a study designed to test the biological and immunological activity of anantibody called AFM13 when given to you intravenously (the infusion of liquid substances directly into a vein). There are 6 groups called cohorts, each cohort consists of 3 research subjects who will be treated with different doses and dose regimens of AFM13 to treat your disease. The purpose of this study is to see if AFM13 is safe and effective in the treatment of research subjects with relapsed or refractory cutaneous lymphomas that are CD30 Positive following conventional treatment.